FoodMarble

Idea

Introduction

FoodMarble is a digestive health tech company and has developed a first-of-its-kind personal digestive tracker. The FoodMarble AIRE is a handheld, wireless breath analysis device which, combined with its connected app enables users to measure how well they are digesting different types of food. This helps to overcome problematic digestive symptoms. The core target market is people with persistent digestive problems such as Irritable Bowel Syndrome (IBS) which affects as many as 15-20% of the population and can have a profound impact on quality of life and can make eating no longer enjoyable. FoodMarble AIRE takes the guesswork out of eating and allows people to identify their optimal diet.

Substantial accomplishments to date

• Pre-orders: Before the initial launch, over 8,000 pre-order backers pre-paid a total of almost £1m to be the first to get a device.

• Sales: Almost 20,000 customers / purchases so far across UK, Ireland, US, Australia, New Zealand and mainland Europe.

• Existing Validation: Independently clinically validated by leading digestive health research group out of Auckland University.

• Future Validation: Clinical trial ongoing at Johns Hopkins (Maryland, US), one of the top research hospitals in the world, to validate our next-generation clinical offering.

• Clinical trials: Pilots with 2 leading London hospitals.

• Advisors: High quality clinical advisory board established with some of the top US gastroenterologists on it.

• Strong innovation pipeline including a 2nd generation device and planned clinical device and subscription service.

Monetisation strategy

The key sources of revenue to date are sales via online channels, including foodmarble.com and amazon, as well as some retail customers such as Best Buy in Canada. In addition, FoodMarble has recently onboarded our first clinical customer in the UK and is set to expand clinical sales to the US with a focus on gastroenterologists.

There is also a focus on significantly expanding the online sales channels and developing further retail sales opportunities in Europe and the US.

With future progress FoodMarble will look towards an additional subscription model.

Use of proceeds

With this round of investment:

We’ll launch our clinical offering in the US and UK. Breath analysis has been used in clinical practice, especially by gastroenterologists, for decades. However, this has been performed using bench top devices which are expensive, require specialist skills and are unsuited for use in the home. MedAIRE is the new FoodMarble device being developed for clinicians.

We’ll complete the 2nd generation device, which will offer a deeper analysis of the breath. It will offer enhancements in terms of ease of use, longevity and will be able to detect further gases of interest on the breath.

We’ll leverage AI to provide new services for our users. This will be breakthrough technology for someone with digestive health issues and could make our app and this subscription service a life-time companion for the user.

We’ll build out our team to become the leader in tech-enabled digestive health! We plan to add resources to our sales, marketing, product development, supply chain & logistics and clinical teams.

Investor perks

Please note the business is offering the following investor rewards:

- 25% off to anyone who invests between £1,000 and £2,499

- 50% off to anyone who invests between £2,500 and £4,999

- FREE to anyone who invests £5,000+

Please note that any discounts, rewards and/or offers listed by a company in its campaign are subject to the terms and conditions applied by that company and listed above. It is the company’s responsibility to honour such discounts, rewards and/or offers and Seedrs does not take any responsibility for them.